Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469335 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL2009026 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL29526232 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL7838339 | 0.96 | LMNA (0.64) | TSHRLMNAALDH1A1NPC1RAB9A | |
| Iodide SCHEMBL27148619 | 0.96 | TSHR (0.64) | TSHRLMNAALDH1A1NPC1RAB9A | |
| Formaldehyde SCHEMBL28138818 | 0.94 | TSHR (0.61) | TSHRLMNAALDH1A1NPC1RAB9A | |
| Dinitrophenylene SCHEMBL27704073 | 0.91 | TSHR (0.77) | TSHRLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL6738366 | 0.91 | TSHR (0.76) | TSHRLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL936227 | 0.90 | LMNA (0.57) | TSHRLMNAALDH1A1NPC1RAB9A | |
| Iodide SCHEMBL30804629 | 0.89 | TSHR (0.73) | TSHRLMNAALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| CN-116283668-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2023-06-23 | — | — | CN | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3621951-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | Research Triangle Institute (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| CN-110621656-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018209030-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2018-11-15 | — | — | WO | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | TSHR 569/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | TSHR 569/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | TSHR 569/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | TSHR 569/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | TSHR 916/4885LMNA 3681/4885ALDH1A1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.